RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
ST. PAUL, Minn., Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it…
ValuePenguin finds in 45 states, 2026 Health Insurance Premiums are Increasing by More Than 10%…
In this free webinar, learn about the advantages of leveraging EPQT and AI-powered data quality…
In this free webinar, learn how to identify sources of variability in bioassay method transfers…
In this free webinar, learn how medical devices benefit from modern digital validation strategies. Attendees…
Backed by $14M in seed funding led by Andreessen Horowitz, and pre-seed funding led by…